Product Description
Mechanisms of Action: PPAR-g Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Alliance for Clinical Trials in Oncology
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Liposarcoma, Myxoid
Phase 1: Lymphoma|Multiple Myeloma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
A091202 | P2 |
Completed |
Liposarcoma, Myxoid |
2018-10-04 |
|
NCT01504490 | P1 |
Terminated |
Multiple Myeloma|Lymphoma |
2016-12-01 |